Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Jennifer M. Connelly MD
Professor
Department of Neurology
Division of General

OFFICE ADDRESS:
Clinical Cancer Center
9200 W Wisconsin Ave
Milwaukee, WI 53226

EDUCATION:
08/1994 - 06/1999 B.S., Marquette University, Milwaukee, WI
08/1999 - 06/2003 M.D., Medical College of Wisconsin, Milwaukee, WI

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
07/2003 - 06/2008 Resident, Combined Internal Medicine - Neurology Program, Medical College of Wisconsin Affiliated Hospitals
07/2007 - 06/2008 Chief Resident, Neurology, Medical College of Wisconsin Affiliated Hospitals
09/2008 - 08/2009 Fellow, Neuro-Oncology, Medical College of Wisconsin

FACULTY APPOINTMENTS:
09/01/2008 - 08/31/2009 Instructor, Neurology, Medical College of Wisconsin
09/01/2009 - 06/30/2014 Assistant Professor, Neurology, Medical College of Wisconsin
07/01/2014 - 06/30/2022 Associate Professor, Neurology, Medical College of Wisconsin
07/01/2022 - Present Professor, Neurology, Medical College of Wisconsin

ADMINISTRATIVE APPOINTMENTS:
09/01/2018 - Present Co-Director of the Neuro-oncology Program, Medical College of Wisconsin

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:
06/01/2012 - 06/30/2014 Neurology Residency Program Director, Neurology, Medical College of Wisconsin

HOSPITAL STAFF PRIVILEGES:
09/2008 - Present Froedtert Memorial Lutheran Hospital, 9200 W. Wisconsin Ave., Milwaukee, WI 53226
07/2010 - Present Community Memorial Hospital, W180 N8085 Town Hall Road, Menomonee Falls, WI 53051

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
American Board of Internal Medicine
08/2008
12/2022
American Board of Psychiatry and Neurology
05/2010
12/2022
Certified Diplomate in Neuro-Oncology
09/2013
12/2023
   
Licensure
Number Issue DateExpiration
Wisconsin State License
47505-020
10/2013
10/2021
    

AWARDS AND HONORS:
06/1997 - Present Outstanding Junior Award - All College, Marquette University
06/1999 - Present Top Scholar in Curriculum Award - Biomedical Engineering, Marquette University
06/1999 - Present W.D. Bliss Outstanding Co-op Award, Marquette University
06/1999 - Present Bachelor of Science in Biomedical Engineering, Summa Cum Laude, Marquette University
06/2001 - Present Nominated for Standing Ovation Service Award, Medical College of Wisconsin
06/2001 - Present Bob Herzog Alumni Scholarship, Medical College of Wisconsin
05/2003 - Present Most Promising Student in Public Health and General Preventative Medicine Award, Medical College of Wisconsin
05/2003 - Present American Academy of Neurology Medical Student Prize for Excellence in Neurology, American Academy of Neurology
06/2005 - Present Top 10 Resident Teachers Award in the Department of Medicine, Medical College of Wisconsin Affiliated Hospitals
06/2006 - Present Neurology Resident Teaching Award, Medical College of Wisconsin Affiliated Hospitals
06/2008 - Present Resident Scholar Award for Excellence in Research and Publications, Medical College of Wisconsin Affiliated Hospitals
02/2013 - Present Medical College of Wisconsin Outstanding Medical Student Teaching Award 2011-2012, MCW
09/2013 - Present Edward J. Lennon Endowed Clinical Teaching Award, MCW
02/2014 - Present Medical College of Wisconsin Outstanding Medical Student Teaching Award 2012-2013, MCW
04/2014 - Present Young Alumna of the Year Award - College of Engineering, Marquette University
06/2014 - Present Special Recognition Award, Department of Neurology, MCW
06/2017 - Present Special Recognition Award, Department of Neurology, MCW
02/2022 - Present Medical College of Wisconsin Outstanding Medical Student Teaching Award 2021-2022, MCw
05/2022 - Present Lee A. Biblo Excellence in Professionalism Award, MCP

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
2003 - Present Wisconsin Neurological Society
2005 - Present American Academy of Neurology
2005 - Present Society of Neuro-Oncology
04/2009 - Present American Society of Clinical Oncology
2009 - Present Radiation Therapy Oncology Group
08/2011 - Present MCW Cancer Center (Research Member)
06/2013 - 12/2020 American College of Physicians (Fellow)

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
07/01/2012 - Present Board Member, Wisconsin Neurological Society
01/01/2014 - 12/31/2017 Vice-President, Wisconsin Neurological Society
01/01/2018 - Present CME Director, Wisconsin Neurological Society

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
01/2017 - Present Leadership Counsel/Dean's Advisory Board, College of Engineering, Marquette University

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Local
Connelly J, Use of Levetiracetam in Seizure Management in Brain Tumor Patients, Department of Neurology Grandrounds, MCW, 07/2008 - Present
Connelly J, Chemotherapeutic agents in Neuro-Oncology, Department of Neurosciences Nursing Lecture Series, Froedert Hospital, 12/2009 - Present
Connelly J, Malkin M, Sabsevitz D., Shots, Carrots and Deep Thoughts - Updates in Neuro-Oncology, Department of Neuroscience Multidisciplinary Grand Rounds, MCW, 02/2013 - Present
Connelly JM, Shots and Electricity. - the future of GBM treatment?, Department of Medicine Grand Rounds, MCW, 01/2015 - Present
Connelly JM, Shots, Electricity and Lasers - the future of GBM treatment, CMH Nursing Grand Rounds, Community Memorial Hospital, 02/2015 - Present
Connelly JM, Shots and Electricity - the future of GBM treatment?, Department of Neurology Grand Rounds, MCW, 03/2015 - Present
Connelly JM, Electric Fields, Vaccines and Viruses - the future of GBM treatment, Department of Neurosurgery Grand Rounds, MCW, 01/2016 - Present
Connelly JM, Electric Fields, Vaccines and Viruses - the future of GBM treatment for nurses., MORE Grand Rounds, Froedtert Hospital, 03/2016 - Present
Connelly J, LaViolette PS, The MCW Brain Cancer Brain Bank. Introduction and Ongoing Studies, Department of Neurology Grand Rounds, MCW, 12/06/2019 - Present
Connelly, LaViolette PS, The MCW Brain Cancer Brain Bank. Introduction and Ongoing Studies., Department of Neurosurgery Grand Rounds, MCW, 01/17/2020 - Present
Connelly J, Pro-Life at End-of-Life: My Thoughts, My Role, My Stories, MCW Students for Life Organization, MCW, 04/15/2021 - Present
 
Regional
Connelly J, Maintaining Maintenance of Certification in Neurology, Wisconsin Neurologic Society Meeting, Waukesha, WI, 10/2013 - Present
Connelly JM, Electric Fields, Vaccines and Viruses - the future of GBM treatment, Grand rounds, Agnesian Hospital, Fond du lac, WI, 01/2016 - Present
Connelly JM, Electric Fields, Vaccines and Viruses - the future of GBM treatment, Grand Rounds, Bellin Hospital, Green Bay, WI, 01/2016 - Present
Connelly JM, Electric Fields, Vaccines and Viruses - the future of GBM treatment, Grand Rounds, Aspirus Hospital, Wausau, WI, 09/2016 - Present
Connelly JM, New Advancements of Gliomas - Multidisciplinary Modality Treatment, Grand Rounds, St. Vincent Hospital, Green Bay, WI, 12/2017 - Present
Connelly J, Who's Who in the World of Gliomas, Agnesian Cancer Center Grand Rounds, Agnesian Health Center, 02/25/2021 - Present
Connelly, JM, "Hey Doc, My Head Hurts!” Initial management of brain tumor patients for the primary care physician., Agnesian Healthcare System Grand Rounds, 03/17/2022 - Present
Connelly, JM, Brain Mets 101 for the primary care physician, Agnesian Healthcare System, 05/05/2022 - Present
 
National
Connelly J, Neurology Board Review for the Internist, American College of Physicians, Schaumberg, IL, 08/2013 - 08/2017
Connelly JM, Palliative Care in Neuro-oncology, American Brain Tumor Association National Conference, Chicago, IL, 07/2014 - Present
Connelly JM, Advances in the Treatment of Glioblastoma using TTFields, American Brain Tumor Association Webinar, https://www.youtube.com/watch?v=biZWfIc4KMw&t=83s, 03/2018 - Present
Connelly J, Engineering from Lab to Clinic - Advancements in Brain Tumor Management, BME Graduate Series - Marquette University and MCW, MCW, 04/30/2021 - Present
 

PEER REVIEWED WORKSHOPS/PRESENTATIONS:
Regional
Connelly J, Role of Levetiracetam in Brain Tumor Patients, Wisconsin Neurological Society Meeting, Wisconsin Dells, WI, 10/2007 - Present
 
National
Connelly J, Shamah C, Davis N, Malkin M, CNS Intravascular Lymphomatosis Responds to Initial Treatment with CNOP and Rituximab, 57th American Academy of Neurology Meeting, Miami, FL, 04/2005 - Present
 

COMMITTEE SERVICE:
Medical College of Wisconsin
02/01/2022 - Present Member, Faculty Mentoring Committee, Department of Neurology, Medical College of Wisconsin
 

MEDICAL COLLEGE TEACHING ACTIVITIES:
Medical Student Education
08/2008 - 01/2015 3rd year medical student lectures in neurology - 8 hours per year
02/2014 - Present Discovery Curriculum - M2 lecture on Neuro-Oncology - yearly presentation
04/2015 Bench to Bedside Teaching - 1st year medical students
01/2017 - Present Presented at the Student Interest Group in Neurology
02/2018 - Present Presented at the Student Interest Group in Neurology
 
Resident and Fellow Education
06/2013 - 06/2019 MCWAH Resident Orientation, Competency-Based Discussions: Patient Safety, Professionalism and Conflict Resolution
 

EXTRAMURAL TEACHING:
Resident and Fellow Education
02/2008 - Present Department of Medicine Resident Lectures, Neuro-Oncology for the Internist (1 hour) - yearly presentation
01/2010 - Present Department of Medicine Resident Lectures, Neuro-Oncology for the Internist (1 hour)
01/2010 Department of Medicine Resident Lectures, Morbidity and Mortality Conference (1 hour)
08/2010 - Present Department of Neurology Resident Lectures, Neuro-Oncology Board Review (3 hours) - yearly
01/2013 - 01/2014 Department of Radiation Oncology Resident Lecture, Neuro-oncology (2 hours) - yearly
03/2013 - Present Department of Oncology Fellows Lecture, Neuro-Oncology review (2 hours) - yearly
05/2013 - Present Department of Psychiatry Resident Lecture, Neuro-oncology Review (2 hours) - yearly
 

PROGRAMMATIC DEVELOPMENTS:
 
 
Clinical Programs
2013 - 2018 Practiced as the only Neuro-oncologist at MCW and grew the volume of new patients during that time by nearly 50%.
 
 


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, Bedakar DP, Schmainda KM. "Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity." J Magn Reson Imaging, vol. 21, no. 3, Mar. 2010, pp. 538-548. PMID 20187195.
2. Ellingson BM, Malkin MG, Rand SD, LaViolette PS, Connelly JM, Mueller WM, Schmainda KM. "Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas." J Neurooncol, vol. 102, no. 1, Mar. 2011, pp. 95-103. PMID 20798977.
3. Ellingson BM, LaViolette PS, Rand SD, Malkin MG, Connelly JM, Mueller WM, Prost RW, Schmainda, KM. "Spatially Quantifying Microscopic Tumor Invasion and Proliferation using a Voxel-wise Solution to the Glioma Growth model and Serial Diffusion MRI." Magn Reson Med, vol. 65, no. 4, Apr. 2011, pp. 1131-43. PMID 21413079.
4. LaViolette PS, Cohen A, Prah MA, Rand SD, Connelly J, Malkin MG, Mueller WM, Schmainda KM. "Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma." Neuro Oncol, vol. 15, no. 4, Apr. 2013, pp. 442-50. PMID:23382287.
5. Cohen AD, LaViolette PS, Prah M, Connelly J, Malkin MG, Rand SD, Mueller WM, Schmainda KM. "Effects of perfusion on diffusion changes in human brain tumors." J Magn Reson Imaging, vol. 38, no. 4, Oct. 2013, pp. 868-75. PMID:23389889
6. Schmainda KM, Prah M, Connelly J, Rand SD, Hoffman, RG, Mueller W, Malkin M. "Dynamic Susceptibility Contrast Agent MRI Measures of relative Cerebral Blood Volume (rCBV) Predicts Response to Bevacizumab in Brain Tumor Patients." Neuro Oncol, vol. 16, no. 6, Jun. 2014, pp. 880-888. 24431219.
7. Heroux MS, Chesnik MA, Halligan BD, Al-Gizawly M, Connelly JM, Mueller WM, Rand SD, Cochran EJ, Laviolette PS, Malkin MG < Schmainda KM, Mirza SP. "Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomics." Physiol Genomics, vol. 46, no. 13, Jul. 2014, pp. 467-481. PMID 24803679.
8. LaViolette PS, Mickevicius NJ, Cochran EJ, Rand SD, Connelly J, Bovi J, Malkin MG, Mueller WM, Schmainda KM. "Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma." Neuro Oncol, vol. 16, no. 12, Dec. 2014, pp. 1599-1606. PMID: 25059209.
9. Quirk BJ, Branda! G, Donion S, Vera JC, Mang TS, Foy AB, Lew SM, Girotti A W, Jogal S, LaViolette PS, Connelly JM, Whelan HT. "Photodynamic therapy (PDT) for malignant brain tumors - where do we stand?" Photodiagnosis Photodyn Ther, vol. 12, no. 3, Sep. 2015, pp.530-44. PMID: 25960361.
10. Mickevicius NJ, Carle AB, Bluemel T, Santarriaga S, Schloemer F, Shumate D, Connelly J, Schmainda KM, LaViolette PS. "Location of brain tumor intersecting white matter tracts predicts patient prognosis." J Neurooncol, vol. 125, no. 2, Nov. 2015, pp. 393-400. PMlD: 26376654.
11. McGarry SD, Hurrell SL, Kaczmarowski AL, Cochran EJ, Connelly JM, Rand SD, Schmainda KM, LaViolette PS. "Magnetic resonance imaging based radiomic profiles predict patient prognosis in newly diagnosed glioblastoma prior to therapy." Tomography, vol. 2, no. 3, Sep. 2016, pp. 223-228. PMID 27774518.
12. Connelly J, Hormingo A, Mohilie N, Hu J, Chaudhry A, Blondin N. "Planning TTFields Treatment Using the NovoTAL Sysem- Clinical Scenarios Beyond the Use ofMRI Contrast Enhancement. A Clinical Case Series and Commentary." BMC Cancer, vol. 16, Nov. 2016, pp. 842-851. PMID: 27809808.
13. Nguyen HS, Milbach N, Hurrell SL, CochranE, Connelly J, Bovi JA, Schultz CJ, Mueller WM, Rand SD, Schmaind KM, LaViolette PS. "Progressing bevacizumab-induced diffusion restriction is associated with coagulative necrosis surrounded by viable tumor and decreased overall survival in patients with recurrent glioblastoma." AJNR AM J Neuroradiol, vol. 37, no. 12, Dec. 2016, pp. 2201-2208. PMID: 27492073.
14. Trusheim J, Dunbar E, Battiste J, Iwamoto F, Mohilie N, Damek D, Bota D, Connelly J. "A State-of-the-art Review and Guidelines for Tumor Treatment Planning and Patient Follow-up in Glioblastoma." CNS Oncol, vol. 6, no. 1, Jan. 2017, pp. 29-43. PMID 27628854.
15. Doan N, Nguyen H, Montoure A, AI -Gi zawiy M, Mueller W, Kurpad S, Rand S, Connelly J, Chitambar C, Schmainda K, Mirza S. "Acid ceramidase is a novel drug target for pediatric brain tumors." Oncotarget, vol. 8, no. 15, Apr. 2017, pp. 24753-24761. PMID 28445970.
16. Doan NB, Ngu yen HS, A l-Gizawiy MM, Muell er WM, Sabbadini RA , Rand SD, Connelly JM, Chitambar CR, Schmainda KM, Mirza SP. "Acid ceramidase confers radioresistance to glioblastoma cells." Oncol Rep, vol. 28, no. 4, Oct. 2017, pp. 1932-1940. PMID 28765947.
17. Doan NB, Alhajala H, AI-Gizawiy MM, Mueller WM, Rand SD, Connelly JM, Cochran EJ, Chitambar CR, Clark P, Kuo J, Schmainda KM, Mirza SP. "Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency." Oncotargt, vol. 8, no. 68, Dec. 2017, pp. 112662-112674. PMID: 29348854.
18. Prah MA, AI-Gi zawi y MM, Mueller WM, Cochran EJ , Hoffmann RG, Connelly JM , Schmainda KM. "Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics." J Neurooncol, vol. 136, no. 1, Jan. 2018, pp. 13-21. PMID 28900832.
19. Kapke JT, Schneidewend RJ, Jawa ZA, Huang C, Connelly JM, Chitambar CR. "High Dose Intravenous Methotrexate in the Management of Breast Cancer with Leptomeningeal Disease: Case Series and Review of the Literature." Hematol Oncol Stem Cell Ther, vol. 12, no. 4, Dec. 2019, pp. 189-193. PMID 31629723.
20. Verhaak R, GLASS Consortium (Connelly J - contributing author), et al. "Longitudinal Molecular Trajectories of Diffuse Glioma in Adults." Nature, vol. 576, no. 7785, Dec. 2019, pp. 112-120. PMID 31748746.
21. Lee EQ, Zhang P, Wen PY, Gerstner ER, Reardon DA, Aldape KD, deGroot JF, Pan E, Raiser JJ, Kim LJ, Chmura SJ, Robins HI, Connelly JM, Battiste JD, Villano JL, Wagle N, Merrel RT, Wendland MM, Mehta MP. "NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma." Cancer, vol. 126, no 12, Jun. 2020, pp. 2821-2828. PMID 32154928.
22. Bobholz SA, Lowman AK, Barrington A, Brehler M, McGarr S, Cochran EJ, Connelly J, Mueller WM, Agarawal M, O’Neill D, Nencka AS, Banerjee A, LaViolette PS. "Radiomic Features of Multiparametric MRI Present Stable Associations With Analogous Histologic Features in Patients with Brain Cancer." Tomography, vol. 6, no. 2, Jun. 2020, pp. 160-169. PMID 32548292.
23. Bovi JA, Prah MA, Retzlaff AA, Schmainda KM, Connelly JM, Rand SD, Marszalkowski CS, Mueller WM, Siker ML, Schultz CJ. "Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes." Int J Radiat Oncol Bill Phys, vol. 108, no. 4, Nov. 2020, pp. 979-986. PMID 32599030.
24. Brehler M, Lowman AK, Bobholz S, McGarry SD, Connelly J, Cochran E, LaViolette PS. "Quantitative analysis of Alzheimer’s disease pathology in glioblastoma patients." SPIE. Feb. 2021, Online Only.
25. GLASS Consortium (Connelly J - contributing co-author). "Longitudinal analysis of diffuse glioma reveals 1 cell state dynamics at recurrence associated with changes in genetics and the microenvironment." Submitted to Cell Apr. 2021.
26. Griffiths C, Connelly J, Chaudhary LN. "Sudden Paralysis." JAMA Oncology, May 27, 2021. PMID 34042938.
27. Orr M, Findling J, Zwagerman N, Connelly J, Albano K, Bovi J. "ACTH secreting pituitary carcinoma: Rare, durable response to concurrent chemotherapy and re-irradiation with a review of the literature." Adv Radiat Oncol. Sept. 2021. PMID 34849427
28. Connelly JM, Prah MA, Santos F, Mueller W, Cochran E, Schmainda K. "MRI Mapping of Brain Tumor Burden: Clinical Implications  for Neurosurgical Management: Case Report." Neurosurgery, Sept. 2021. PMID: 34661110
29. Reith TP, Prah MA, Choi EJ, Lee J, Wujek R, Al-Gizawiy M, Chitambar CR, Connelly JM, Shaminda KM. "Basal Ganglia Iron Content Increases with Glioma Severity Using Quantitative Susceptibility Mapping: A Potential Biomarker of Tumor Severity." Tomography, Mar. 2022. PMID 35314642.
30. Bobholz SA, Lowman AK, Brehler M, Kyereme F, Duenweg SR, Sherman J, McGarry S, Cochran EJ, Connelly J, Mueller WM, Agarwal M, Banerjee A, LaViolette PS. "Radio-pathomic maps of cell density identify glioma invasion beyond traditional MR imaging defined margins." AJNR Am J Neuroradiol. May 2022. PMID 35422419
31. Bureau BL, Connelly JM, Barkhaus PE, Brennan R. "Numb Chin Syndrome: Atypical presentation of metastatic breast cancer." Submission pending.
 
Books, Chapters, and Reviews
1. Connelly, J., Malkin, M. : Environmental Risk Factors for Brain Tumors. Curr Neurol Neurosci Rep 7:208-214, 2007.
2. Connelly J, Weissman D. Fast Facts and Concepts #229 Seizure Management in the Dying Patient. http://www.mcw.edu/EPERC/FastFactsIndex. April 2010.
 
Abstracts
1. Connelly J, Malarcher A, Greenlund K, Martin L. Stroke Impact Worse than Coronary Heart Disease or Diabetes on Functional Activities. Stroke 2004;35:321.
2. Connelly J, Shamah C, Davis N, Malkin M. CNS Intravascular Lymphomatosis Responds to Initial Treatment with CNOP and Rituximab. Neurology 2005;64:A19, A51.
3. Shamah C, Connelly J, Malkin M, Davis N. Intravascular Lymphomatosis of the CNS Responds to Initial Treatment with CNOP and Rituximab. ASCO Procedings 2005.
4. Connelly J, Mushtaq R, Krouwer H, Malkin M. Levetiracetam and seizure freedom in primary and metastatic brain tumors: a retrospective review. Neuro-Oncology 2007;9(4):525.
5. Connelly J, Malkin MG, Krouwer H, Mushtaq R. Seizure freedom with levetiracetam therapy in brain tumor patients. Epilepsia 2007;48(S6):336.
6. Connelly J, Mushtaq R. Krouwer H, Mueller W, Malkin M. The role of surgical resection for seizure control in primary and metastatic brain tumors: a retrospective study. Neurology 2008;70(11)[Suppl 1]:A296.
7. Schmainda KM, Bedekar D, Rand SD, Connelly J, Kurpad S, Krouwer GH, Paulson ES, Malkin MG, DSC-MRI measures of rCBV predict response to bevacizumab treatment more reliably than standard MRI in patients with recurrent high-grade gliomas. Proc Int Soc Magn Reson Med 2009; 17: 985.
8. Ellingson BM, Bedekar DP, Malkin MG, Rand SD, Hoyt A, Connelly J, Kurpad SN, Schmainda KM. Hybrid functional diffusion and perfusion maps for evaluation of gliomas. Proc Int Soc Magn Reson Med 2009; 17: 1000.
9. Ellingson BM, Malkin MG, Rand SD, Hoyt A, Connelly J, Bedekar DP, Kurpad SN, Schmainda KM. Comparison of cytotoxic and anti-angiogenic treatment responses using functional diffusion maps in FLAIR abnormal regions. Proc Int Soc Magn Reson Med 2009; 17: 1010. **1st Place Poster in Cancer Imaging **
10. LaViolette P, Ellingson BM, Malkin MG, Connelly JM, Schmainda KM. Mapping invasion at tumor boundaries using diffusion weighted MRI. Neuro-Oncology 2009;11(5):600.
11. Ellingson BM, Malkin MG, Rand SD, Connelly JM, Schmainda KM. Long-term clinical monitoring of gliomas using functional diffusion maps. Neuro-Oncology 2009;11(5):672.
12. Ellingson BM, Malkin MG, Rand SD, Connelly JM, Bedekar D, Schmainda KM. Evaluation of cytotoxic and anti-angiogenic treatments using functional diffusion maps in FLAIR abnormal regions. Neuro-Oncology 2009;11(5):672.
13. Ellingson BM, Malkin MG, Rand SD, Connelly JM, Bedekar D, Schmainda KM. Hybrid functional diffusion and perfusion maps for evaluation of gliomas. Neuro-Oncology 2009;11(5):672.
14. Schmainda KM, Bedekar D, Rand SD, Connelly JM, Krouwer HG, Malkin M. MRI measures of rCBV predict response to bevacizumab treatment more reliably than standard MRI in patients with recurrent high-grade gliomas. Neuro-Oncology 2009;11(5):673
15. Connelly J, Harrington A, Kroft S, Ho K, Fenske T, Malkin M. Methotrexate-induced CNS Hodgkin-like lymphoproliferative disorder: a case report. Neuro-Oncology 2009;11(5):245.
16. LaViolette PS, Ellingson BM, Connelly JM, Malkin MG, Rand SD, Schmainda KM. "Assessment of Invasion and Recurrence in Glioblastoma Multiforme using Diffusion Weighted MRI Edge Characteristics of Contrast Enhancing Tumor". Proc. Intl. Soc. Mag. Reson. Med., 18th Annual Meeting, Stockholm, Sweden (05/2010).
17. Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quincey C, LaViolette PS, Bedekar DP, Schmainda KM. "Validation of functional diffusion maps (fDMs) as cellularity biomarkers in human gliomas."Proc. Intl. Soc. Mag. Reson. Med., 18th Annual Meeting, Stockholm, Sweden (05/2010). (W.S. Moore Young Investigator Award Finalist).
18. Ellingson BM, Rand SD, Malkin MG, Prost R, Connelly JM, LaViolette PS, Bedekar DP, Schmainda KM. "Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise analytical solution to a glioma growth model and serial diffusion MRI." Proc. Intl. Soc. Mag. Reson. Med., 18th Annual Meeting, Stockholm, Sweden (05/2010).
19. Ellingson BM, Malkin MG, Rand SD, Connelly JM, LaViolette PS, Bedekar DP, Schmainda KM. "Functional diffusion maps (fDMs) applied to FLAIR abnormal regions can detect pseudoprogression from recurrent tumor in malignant gliomas." Proc. Intl. Soc. Mag. Reson. Med., 18th Annual Meeting, Stockholm, Sweden (05/2010).
20. Ellingson BM, Malkin MG, Rand SD, Connelly JM, LaViolette PS, Bedekar DP, Schmainda KM. "Graded functional diffusion maps (fDMs) applied to whole brain: A sensitive imaging biomarker for monitoring brain tumor growth and invasion." Proc. Intl. Soc. Mag. Reson. Med., 18th Annual Meeting, Stockholm, Sweden (05/2010).
21. Bedekar D, Jensen T, Rand S, Malkin MG, Connelly J, Schmainda KM. "Delta T1 Method: An automatic post-contrast ROI selection technique for brain tumors." Proc. Intl. Soc. Mag. Reson. Med., 18th Annual Meeting, Stockholm, Sweden (05/2010).
22. Schmainda KM, Bedekar D, Rand SD, Connelly J, Malkin M. "Initial rCBV predicts response to bevacizumab in patients with high-grade gliomas." Proc. Intl. Soc. Mag. Reson. Med., 18th Annual Meeting, Stockholm, Sweden (05/2010).
23. LaViolette PS, Al-Gizawiy M, Cochran E., Rand SD, Malkin MG, Connelly J, Mueller WM, Schmainda KM. In-vivo Biomarkers for Brain Tumor Vasculature and Cellularity Validated with Ex-vivo Tissue. 19th Annual Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM), Montreal, Quebec, Canada, 2011.
24. PS. LaViolette, AD. Cohen, E. Cochran, M. Prah, CJ. Hartman, JM. Connelly, SD. Rand, MG. Malkin, WM. Mueller, KM. Schmainda. ADC-FLAIR Mismatch Excluding Enhancement (AFMEE), a Potential Biomarker of Tumor Infiltration. Society for Neuro-Oncology Annual meeting Orange County, CA. 2011.
25. PS. LaViolette, E. Cochran, M. Al-Gizawiy, JM. Connelly, MG. Malkin, SD. Rand, WM. Mueller, KM. Schmainda. Voxelwise Correlation of In-Vivo MRI to Ex-Vivo Brain Tumor Histology. Society for Neuro-Oncology Annual meeting Orange County, CA. 2011.
26. B. Bodager, P.S. LaViolette, D. Bedekar, J. Connelly, M.G. Malkin, S.D. Rand, W.M. Mueller, K.M. Schmainda. Comparison of MRI-based biomarkers of tumor aggressiveness to genetic biomarkers of prognosis in Glioblastoma Multiforme. Oral Presentation at RSNA 2011, Chicago, IL.
27. P.S. LaViolette, A.D. Cohen, S.D. Rand, J. Connelly, M.G. Malkin, W.M. Mueller, and K.M. Schmainda. Vascular normalization measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in recurrent glioblastoma. 20th Annual Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM), Melbourne Australia, 2012. (Pending)
28. P.S. LaViolette, M.A. Prah, M. Al-Gizawiy, E.J. Cochran, S.D. Rand, J. Connelly, M.G. Malkin, W.M. Mueller, and K.M. Schmainda. Ex-vivo infiltrative brain tumor histologically correlates with decreased ADC and increased rCBV as measured with functional diffusion and perfusion maps. 20th Annual Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM), Melbourne Australia, 2012.
29. P.S. LaViolette, E.J. Cochran, A.D. Cohen, M. Al-Gizawiy, S.D. Rand, J. Connelly, M.G. Malkin, W.M. Mueller, and K.M. Schmainda. Precise ex-vivo histological validation of heightened cellularity in regions of dark ADC in three cases of high-grade glioma. 20th Annual Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM), Melbourne Australia, 2012. Magna Cum Laude Award recipient.
30. Schmainda KM, Prah M, Connelly J, et al. Dynamic Susceptibility Contrast MRI Measures of Standardized rCBV Predict Response to Bevacizumab in HIgh-Grade Brain Tumor Patients. Submitted ISMRM 2012.
31. LaViolette PS, Cohan AD, Cochran E, Prah M, Rand SD, Connelly J, Malkin MG, Mueller WM, Schmainda KM. ICA-DSC derived AVOL, a New Imaging Biomarker of Brain Tumor Vasculature. MCW Research Day 2012. Awarded the non-basic science research award.
32. Sweis R, Lavingia J, Connelly J, Cochran E. Recurrent Intracerebral Schwannoma in a 31 year old male: a Case Report. Society of Neuro-Oncology Meeting, Washingon D.C., 2012.
33. Connelly J. Pseudoprogression in spinal cord glioma: a case report. Society of Neuro-Oncology Meeting. Washington D.C., 2012.
34. P. S. LaViolette, M. Daun, A. D. Cohen, J. Connelly, and K.M. Schmainda. Contrast Dose Dependence of Arterial-Venous Overlap in High-Grade Glioma. 21st Annual Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM), Salt Lake City, UT, 2013
35. LaViolette PS, Daun MK, Cohen AD, Connelly JM, Schmainda KM. Optimizing Repeatability of Independent Component Analysis applied to Dynamic Susceptibility Contrast MRI in 68 Brain Tumor Patients with Five Repeated Scans. Submitted ISMRM 2013.
36. P.S. LaViolette, A.D. Cohen, E. Cochran, M.A. Prah, S.D. Rand, J. Connelly, M.G. Malkin, W.M. Mueller, and K.M. Schmainda.ICA-DSC derived AVOL, a New Imaging Biomarker of Brain Tumor Vasculature. Research Day 2013, Medical College of Wisconsin, Winner of the Merit Award for Best Non-Basic Research.
37. P.S. LaViolette, E. Cochran, A. D. Cohen, M. Al-Gizawiy, J. Connelly, S. D. Rand, M.G. Malkin, and K.M. Schmainda. Reduced diffusion and perfusion in bevacizumab-induced diffusion restricted necrosis versus brain tumor hypercellularity. 21st Annual Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM), Salt Lake City, UT, 2013.
38. P.S. LaViolette, M. Daun, A. D. Cohen, J. Connelly, and K.M. Schmainda. Optimizing Repeatability of Independent Component Analysis applied to Dynamic Susceptibility Contrast MRI in 68 Brain Tumor Patients with Five Repeated Scans. 21st Annual Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM), Salt Lake City, UT, 2013.
39. Daun MK, LaViolette PS, Connelly J, Cohen AD, Schmaind KM. Contrast Dose Dependence of Aterial-Venous Overlap in High-Grade Glioma. Submitted ISMRM 2013.
40. LaViolette PS, Daun MK, Cohen AD, Connelly JM, Schmainda KM. Optimizing Repeatability of Independent Component Analysis applied to Dynamic Susceptibility Contrast MRI in 68 Brain Tumor Patients with Five Repeated Scans. ISMRM 2013.
41. Daun MK, LaViolette PS, Connelly J, Cohen AD, Schmaind KM. Contrast Dose Dependence of Aterial-Venous Overlap in High-Grade Glioma. ISMRM 2013.
42. Mickevicius NJ, Cochran E, Rand SD, Connelly J, Al-Gizawiy M, Schmainda K, LaViolette PS. Brain tumor Hypercellularity Detected in Diffusion Restricted Voxels Outside Contrast Enhancement in Six Human Brains Examined Ex-vivo. ISMRM Meeting. Oral Presentation. May 2014.
43. M. Heroux, M. Chesnik, B.D. Halligan, M. Al-Gizawiy, J. Connelly, W.M. Mueller, S. Rand, E. Cochran, P.S. LaViolette, M. Malkin, K.M. Schmainda and S.P. Mirza. Identification of Glioblastoma Multiforme A Priori Bevacizumab Response Biomarkers by Mass Spectrometry-Based Label-Free Quantitative Proteomics. ASMS 2014, 62nd ASMS Conference on Mass Spectrometry and Allied Topics. June 15-19, Baltimore, MD
44. N.J. Mickevicius, E.J. Cochran, S.D. Rand, J. Connelly, K.M. Schmainda, and P.S. LaViolette. Imaging based, histology trained maps (IBHTMs) of brain tumor cellularity predict tumor presence in pathologically confirmed regions sampled ex-vivo. Cancer Imaging Workshop of the International Society of Magnetic Resonance in Medicine (ISMRM), Oral Presentation ,Nov. 2014.
45. N.J. Mickevicius, A. Carle, S. Santarriaga-Escamilla, T. Bluemel, J. Connelly, S. D. Rand, W. M. Mueller, K.M. Schmainda, P. S. LaViolette. Location of glioblastoma intersecting white matter tracts predict patient prognosis and response to bevacizumab prior to therapy. Annual Meeting of the Society for Neuro-oncology, Miami, FL 11/2014
46. N. J. Mickevicius, E.J. Cochran, S. D. Rand, J. Connelly, K. M. Schmainda, and P. S. LaViolette, Brain tumor imaging based, histology trained maps (IBHTMs) of cellularity predict tumor presence in pathologically confirmed regions sampled ex-vivo.. 23rd Annual Meeting of the International Society for Magnetic Resonance in Medicine, Toronto, Canada. May 2015
47. P.S. LaViolette, N. J. Mickevicius, E. J. Cochran, J. Connelly, K. M. Schmainda, and S. D. Rand. Brain tumor cellularity maps trained with co-registered histology predict tumor presence in pathologically confirmed regions sampled ex-vivo. World Molecular Imaging Congress Annual Meeting, Honolulu, HI. Sept. 2015
48. Renu D, Aggarwal P, Cherukuri S, Tata P, Bhat V, Livi C, Rosenberg M, Al-Gizawly M, Mueller W, Connelly J, Schmainda K, Mirza S. Integrated analysis of molecular subtypes in glioblastoma multi forme. Neuro-oncology. 11/2015; 17(suppl 5):v91.
49. Prah M, Connelly J, Schmainda K. Preliminary trends in advanced imaging relative to standard imaging in subjects treated with Optune. Neuro-oncology. 11/2015; 17 (suppl 5):vl67.
50. Laviolette P, Milbach N, Connnelly J, RandS, Schmainda KM, Cochran E. Pathologically confirmed viable tumor surrounds regions of progressively expanding diffusion-restricted necrosis following bevacizumab treatment. Neuro-oncology. 11/2015; 17(suppl 5):v 164.
51. Lee E, Zhang P, Wen P, Gerstner E, Reardon D, Aldape K, J deGroot J, Choe K, Raizer J, Kim, L Chmura S, Robins HI, Connelly J, Battiste J, Villano J, Wagle N, Merrell R, Wendland M, Mehta M. NRG Oncology/RTOG 1122: Phase II Double-Blinded, Placebo-Controlled Study of Bevacizumab with or without AMG 386 in Patients with Recurrent Glioblastoma or Gliosarcoma. Neuro-oncology. 11/2015.
52. H.S. Nguyen, N. Milbach, S.L. Hurrell, E. Cochran, J. Connelly, M. Al-Gizawiy, J. Bovi, S.D. Rand, K.M. Schmainda, and P.S. LaViolette. Progressing bevacizumab induced diffusion restriction is associated with coagulative necrosis surrounded by viable tumor and decreased overall survival in recurrent glioblastoma patients. 24th Annual Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM), Singapore, Oral Presentation, May 2016.
53. P.S. LaViolette. H.S. Nguyen, S.L. Hurrell, N. Milbach, J. Connelly, E. Cochran, K.M. Schmainda, and S.D. Rand. Progressive bevacizumab induced diffusion-restricted lesions indicate coagulative necrosis surrounded by non-enhancing tumor and are associated with decreased survival in recurrent glioblastoma patients. Annual meeting of the American Society for Neuroradiology (ASNR), Washington, DC. May 22nd 2016. Finalist for the Cornelius Dyke Award
54. Al-Gizawiy M, Doan N, Mueller W, Connelly J, Schmainda K, Mirza S. Glioma classification using the novel biomarker acid ceramidase. Neuro-Oncology, Vol 18, Issue suppl_6, 1 Nov 2016, vi109–vi110.
55. Doan N, Al-Gizawiy M, Mueller W, Connelly J, Schmainda K, Mirza S. Acid ceramidase confers radioresistance to glioblastoma cells. Neuro-Oncology, Volume 18, Issue suppl_6, 1 November 2016, Page vi37.
56. Connelly J, Hormingo A, Mohilie N, Hu J, Chaudhry A, Blondin N. Development of practice algorithms to guide treatment planning with TTFields for the management of glioblastoma. Neuro-Oncology, Volume 18, Issue suppl_6, 1 November 2016, Page vi129.
57. Hurrell SL, Cochran E, McGarry Sean D, Kaczmarowski AL, Connelly J, Mueller W, Rand SD, Schmainda KM, LaViolette PS. Predictive cytological topography, a radiopathomics approach, highlights regions of pathologically confirmed non-enhancing hypercellular tumor in glioblastoma patients at autopsy. 25th Annual Meeting of ISMRM, Honolulu, HI, Power-Pitch oral presentation April 2017. Top 5% Abstract.
58. S. Hurrell, S. McGarry, J. Connelly, and P.S. LaViolette. Recurrent glioblastoma pathologically proven in subtle hyperperfused regions otherwise appearing normal on conventional imaging. Annual meeting of the American Society for Neuroradiology (ASNR), Long Beach CA. Oral Presentation. April 2017.
59. Hurrell S, Cochran E, Mueller WM, McGarry S, Schultz CJ, Siker M, Rand S, LaViolette PS, Schmainda KM, Connely JM. “Case report: delayed development of pseudoprogression in 2 glioblastoma patients treated with TTFields.” 22nd Annual Meeting of the Society of Neuro-Oncology, San Francisco, CA. November 2017, RARE-16.
60. Hurrell S, Cochran, McGarry S, Connelly JM, Schmainda KM, Rand S, Mueller WM, LaViolette P. “Autopsy study on the effects of tumor treatment fields in recurrent glioblastoma: preliminary results and trial design.” 22nd Annual Meeting of the Society of Neuro-Oncology, San Francisco, CA. November 2017, ACTR-44.
61. Prah MA, Connelly JM, and Schmainda KM. MRI-perfusion derived fractional tumor burden (FTB) is predictive of overall and progression free survival in newly diagnosed glioblastoma following concomitant 30 chemoradiotherapy. in Proceedings International Society of Magnetic Resonance in Medicine. 2017. Honolulu, Hawaii. P 707.
62. Prah MA, Connelly JM, and Schmainda KM. MRI-perfusion derived Fractional Tumor Burden (FTB) stratifies survival in recurrent glioblastoma following treatment with bevacizumab. in Proceedings of the International Society of Magnetic Resonance in Medicine, 25th Annual Meeting. 2017. Honolulu, Hawaii. P 708
63. Connelly JM, Prah MA, Schmainda KM. “Advanced perfusion and diffusion MR imaging in glioblastoma patients treated with tumor treating fields (TTFields) as first-line therapy.” 22nd Annual Meeting of the Society of Neuro-Oncology, San Francisco, CA. November 2017, NIMG-67
64. Al-Gizawiy MM, Wujek RT, Alhajala HS, Doan NB, Knipstein J, Connelly JM, Mirza SP, Chitamber CR, Schmainda KM. “In vitro pre-treatment of cell lines produces a robust in vivo xenograft model mimicking recurrent glioblastoma.” 22nd Annual Meeting of the Society of Neuro-Oncology, San Francisco, CA. November 2017, TMOD-08.
65. S.L. Hurrell, S.M. McGarry, J.M. Connelly, P.S. LaViolette. Histological validation of glioblastoma radiomic profiles at autopsy. American Society of Neuroradiology, 6/2018, Vancouver Canada, Oral Presentation.
66. A. Barrington, A. Lowman, E.J. Cochran, S. Hurrell, S. McGarry, J. Connelly, S.D. Rand, W. Mueller, and P.S. LaViolette. Autopsy study on the effects of tumor treatment fields in recurrent glioblastoma: preliminary results. Society for Neuro-Oncology, 11/2018, New Orleans LA, Poster Presentation.
67. S.L. Hurrell, S.M. McGarry, E.J. Cochran, J.M. Connelly, S.D. Rand, W.M. Mueller, P.S. LaViolette. Autopsy analysis of the overlap of radiomic profiles associated with poor overall survival and predictive maps of tumor cellularity in glioblastoma patients. 27th Annual Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM), Paris France. 6/2018 Poster Presentation.
68. Al-Gizawiy MM, Wujek R, Prah M, Alhajala H, Doan N, Knipstein J, Connelly J, Mirza S, Chitambar C, Schmainda K. “Advanced MR imaging characterization of a novel in vivo xenograft model mimicking recurrent glioblastoma.” Proceedings International Society of Magnetic Resonance in Medicine, June, 2018. P 2131.
69. Schmainda K, Prah M, Wujek R, Connelly J. “Moving towards a DSC-MRI Consensus: A new single dose option for standardized rCBV.” Proceedings International Society of Magnetic Resonance in Medicine, June, 2018. P 1233.
70. Prah M, Connelly J, Rand S, and Schmainda K. Quantification of DSC-MRI derived fractional tumor burden (FTB) is predictive of survival in newly diagnosed glioblastoma following concomitant chemo- radiotherapy. In: Proceedings of the ASNR 56th Annual Meeting, June 2-7, 2018, Vancouver, BC, CAN. http://ww3.aievolution.com/asn1801/index.cfm?do=abs.viewAbs&abs=2110
71. A. Barrington, A. Lowman, E.J. Cochran, S. Hurrell, S. McGarry, J. Connelly, S.D. Rand, W. Mueller, and P.S. LaViolette. Autopsy study on the effects of tumor treatment fields in recurrent glioblastoma: preliminary results. Society for Neuro-Oncology, 11/2018, New Orleans LA, Poster Presentation.
72. A. Lowman, A. Barrington, B. Ellingson, S. Bobholz, J. Connelly, S. McGarry, J. Bukowy, A. Nencka, P.S. LaViolette. A precise comparison of heterogeneous pathological features of glioblastoma at autopsy to T1 subtraction maps. American Society of Neuroradiology, 5/2019, Boston MA, Oral Presentation.
73. Lynch C, Hartsell WF, Chang JHC, Sweeney PJ, Kalapurakal JA, Diaz AZ, Chandler JP, Tsung AJ, Prabhu V, Bovi JA, Connelly JM, Grimm S, Raiser JJ, Sarma K, Conterato DJ, Rajendran RR, Gondi V. Toxicity, Disease Control, and Survival Following Proton Therapy Fractionated Re-Irradiation for Recurrent Intracranial Meningioma Not Amenable to Radiosurgery. Accepted Astro 9/2019.
74. Lynch, C, Hartsell WF, Chang JHC., Sweeney P, Kalapurakal J, Diaz A, Chandler J, Tsung A, Prabhu V, Bovi JA, Connelly JM, Grimm S., Raizer JJ, Sarma K, Conterato V, Rajendran R, Gondi V. Toxicity, Disease Control, and Survival Following Proton Therapy-Fractionated Re-Irradiation for Recurrent Intracranial Meningioma Not Amenable to Radiosurgery. Radiation Oncology. 105:2019:E116-117.
75. S. Bobholz, A. Lowman, J. Connelly, S. McGarry, EJ Cochran, J. Bukowy, A. Nencka, A. Barrington, PS. LaViolette. Preservation between histologic and radiomic features in brain cancer. Radiomics 2019, Clearwater Beach, FL. Oral Presentation
76. Prah MA, Hu LS, Boxerman JL, Quarles C, Connelly JM, Schmainda KM. Evaluation of Fractional Tumor Burden (FTB) fidelity using a no-preload, low-flip angle dynamic susceptibility contrast MRI acquisition scheme. ISMRM May 2019.
77. Michael Brehler, Sean McGarry, Allison Lowman, Samuel Bobholz, Jennifer Connelly, Elizabeth Cochran, Peter S. LaViolette. Connection between Alzheimer's disease and Glioblastoma, Milwaukee Neuroscience Research Day 2019, Milwaukee WI, Poster Presentation.
78. S. Bobholz, A. Lowman, J. Connelly, S. McGarry, J. Bukowy, A. Nencka, A. Barrington, PS. LaViolette. Comparison of MRI Radiomics and Histology Features in Glioblastoma. 57th Annual Meeting of the American Society of Neuroradiology (ASNR), Boston Massachusetts, 5/2019 Oral Presentation
79. Samuel Bobholz, Allison Lowman, Jennifer Connelly, Sean McGarry, John Bukowy, Andrew Nencka, Alexander Barrington, and Peter S. LaViolette. Comparison of MRI and Histology Radiomics in Glioblastoma Presented at American Society of Neuro Radiology Annual Meeting 2019 (oral presentation)
80. Allison Lowman, Alexander Barrington, Elizabeth Cochran, Jennifer Connelly, Wade Mueller, Peter LaViolette. Comparison of cellular features at autopsy in glioblastoma patients with standard of care treatment and the addition of tumor treatment fields. 24th Annual Meeting of the Society for NeuroOncology (SNO), 11/2019, Phoenix, AZ, Poster Presentation.
81. Samuel Bobholz, Allison Lowman, Jennifer Connelly, Sean McGarry, John Bukowy, Andrew Nencka, Anjishnu Banerjee, Peter LaViolette. Ensemble-based machine learning algorithm predicts cellular density from clinical MRI in brain cancer patients. Presented at GSA Symposium 2020 (poster)
82. Samuel Bobholz, Allison Lowman, Jennifer Connelly, Sean McGarry, John Bukowy, Andrew Nencka, Anjishnu Banerjee, Peter S. LaViolette. Comparison of radiomics-based and deep learning techniques for predicting nuclei density in brain cancer patients from MRI. 29th Annual Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM) 2020, Sydney AU (Rescheduled), E-Poster Presentation.
83. Samuel Bobholz, Allison Lowman, Jennifer Connelly, Sean McGarry, John Bukowy, Andrew Nencka, Anjishnu Banerjee, Peter S. LaViolette. Preliminary MRI-based cellularity predictions indicate abnormal pathology in brain cancer patients at autopsy. American Society of Neuroradiology 2020, late breaking digital poster.
84. Samuel Bobholz, Allison Lowman, Jennifer Connelly, Sean McGarry, John Bukowy, Andrew Nencka, Anjishnu Banerjee, Peter S. LaViolette. MRI signatures associated with pathologically relevant histological features of brain cancer at autopsy. 29th Annual Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM) 2020, Sydney AU (Rescheduled), E-Poster Presentation.
85. A. Lowman, S. Bobholz, M. Brehler, S. McGarry, E. Cochran, J. Connelly, P.S. LaViolette. A precise comparison of T1-weighted contrast enhancement and pathological features of glioma at autopsy in nine patients. 58th Annual Meeting of the American Society of Neuroradiology (ASNR), Las Vegas, NV, 6/2020 Oral Presentation
86. Straza WM, Bovi JA, Puckett L, Siker ML, Saeed H, Ahunba EE, Chen X, Mueller W, Santos Pinheiro F, Connelly JM, Hall WA, Li A, Schultz CJ, Paulson ES. Quantitative Imaging of Patients Undergoing Radiotherapy for Primary Gliomas Using A 1.5 Tesla MR Linac. ASTRO Nov. 2020.
87. Samuel Bobholz, Allison Lowman, Jennifer Connelly, Sean McGarry, John Bukowy, Andrew Nencka, Anjishnu Banerjee, and Peter S. LaViolette. Comparison of radiomics-based and deep learning techniques for predicting nuclei density in brain cancer patients from MRI. 29th Annual Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM) 2020, Sydney AU (Rescheduled), (digital poster)
88. Samuel Bobholz, Allison Lowman, Jennifer Connelly, Sean McGarry, John Bukowy, Andrew Nencka, Anjishnu Banerjee, Peter S. LaViolette. Information-based assessment of the radiomic-histomic relationship in brain cancer patients. 29th Annual Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM) 2020, Sydney AU (Rescheduled), Oral Presentation.
89. Samuel Bobholz, Allison Lowman, Michael Brehler, Savannah Duenweg, Sean McGarry, Fitzgerald Kyreme, Elizabeth Cochran, Jennifer Connelly, Wade Mueller, Mohit Agarwal, Darren O’Neil, Anjishnu Banerjee, Peter LaViolette. Radio-pathomic machine learning models trained with autopsy tissue samples aligned to MP-MRI predict histopathological features in brain cancer patients. 30th Annual Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM), Virtual 2021 (oral presentation).
90. Samuel Bobholz, Allison Lowman, Michael Brehler, Savannah Duenweg, Sean McGarry, Fitzgerald Kyreme, Elizabeth Cochran, Jennifer Connelly, Wade Mueller, Mohit Agarwal, Darren O’Neil, Anjishnu Banerjee, Peter LaViolette. Pathological validation of MP-MRI intensity-based signatures in brain cancer patients using autopsy tissue samples. 30th Annual Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM), Virtual 2021 (oral presentation).
91. A Lowman, S Bobholz, J Connelly, E Cochran, W Mueller, M Brehler, F Kyereme, J Sherman, S Duenweg, PS LaViolette. Measurement of treatment dependent glioblastoma cell density in T1-weighted contrast enhancement at autopsy. ASCO 2021 Accepted for digital presentation.